Compare Ingersoll Rand (IR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ingersoll Rand vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Ingersoll Rand trades at $77.95 (market cap $30.24B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M). The key difference: Ingersoll Rand is far larger — about 30.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Ingersoll Rand pays a 0.1% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ingersoll Rand for 9 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IR | MRVI | |
|---|---|---|
Market Cap | $30.24B | $977.37M |
Volume | 2,589,571 | 2,742,564 |
Sector | Industrials | Health |
52-Week High | $98.76 | $9.00 |
52-Week Low | $68.54 | $2.83 |
Typical Hold Time | 9 Days | 0 Days |
Enterprise Value | $33.90B | $1.08B |
Dividend Yield | 0.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ingersoll Rand (IR) trades at $78.95, down 0.18% with a bullish technical signal. The company shows strong fundamentals with Q2 2026 EPS beating estimates at $0.86 versus $0.827 expected, marking three consecutive quarterly beats. Revenue guidance was raised to 4.5%-6.5% for 2026, with improving demand across business cycles. Analyst consensus is bullish with a $90.60 price target, representing 15% upside potential from current levels.
The outlook remains positive with accelerating long-cycle orders and strategic acquisitions expanding capabilities. Key risks include margin compression and elevated P/E ratio of 32.62. Institutional ownership increased with HSBC boosting its position by 12.9% in Q2 2026. The stock offers growth potential but requires monitoring of profitability trends and valuation sustainability.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ingersoll Rand
Ingersoll Rand develops industrial technologies for creating and managing flow, pressure, and motion. Its portfolio includes compressors, pumps, vacuum systems, and other equipment used across industrial markets.
Read more on IR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
